Until recently, multi-kinase inhibitors were the only approved therapy for advanced, unresectable HCC, but recent clinical studies have established a role for immune checkpoint inhibitors, including anti-PD-(L)1 therapies, in this disease across multiple contexts (3–10). The gene discussed is CD274; the disease is hepatocellular carcinoma.